• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. International Journal of Pharmacology
  2. Vol 10 (5), 2014
  3. 258-266
  • Online First
  • Current Issue
  • Previous Issues
  • More Information
    Aims and Scope Editorial Board Guide to Authors Article Processing Charges
    Submit a Manuscript

International Journal of Pharmacology

Year: 2014 | Volume: 10 | Issue: 5 | Page No.: 258-266
DOI: 10.3923/ijp.2014.258.266

Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend



Total views 120

Authors


Andleeb Shahzadi

Country: Turkey

Ikbal Sonmez

Country: Turkey

Oruc Allahverdiyev

Country: Turkey

Burak Onal

Country: Turkey

Cemre Kandaz

Country: Turkey

Sibel Ozmen Ozyazgan

Country: Turkey

Ahmet Gokhan Akkan

Country: Turkey

Zeliha Yazici

Country: Turkey

Keywords


  • cardiac troponin-I (cTnI)
  • Cardiotoxicity
  • ciprofloxacin
  • doxorubicin and drug-drug interaction
Research Article

Cardiac Troponin-I (cTnI) a Biomarker of Cardiac Injuries Induced by Doxorubicin Alone and in Combination with Ciprofloxacin, Following Acute and Chronic Dose Protocol in Sprague Dawley Rats

Andleeb Shahzadi, Ikbal Sonmez, Oruc Allahverdiyev, Burak Onal, Cemre Kandaz, Sibel Ozmen Ozyazgan, Ahmet Gokhan Akkan and Zeliha Yazici
The present study investigates the release of cardiac troponin-I (cTnI) as a biomarker of cardiac injuries induced by doxorubicin (Doxo) alone and along with ciprofloxacin (Cipro), following acute and chronic dose protocol in Sprague Dawley rats. In chronic protocol, rats were given multiple intra-peritoneal (i.p) injections of Doxo (1 or 2.5 mg kg-1) alone or in combination with Cipro (20 mg kg-1 daily) and a placebo control. Whereas in acute protocol, rats were subjected to receive single i.p. injection of Doxo (6 or 15 mg kg-1) alone or along with Cipro (20 mg kg-1) and placebo treatment with saline (control). The plasma levels of cTnI were measured by using Enzyme-linked Immuno Sorbent Assay (ELISA) technique. All the treated groups, following acute or chronic dose protocol showed significant increase in cTnI plasma level from 137-248% in comparison to control (p<0.0001). The cTnI plasma levels increased in dose dependent manner after following acute and chronic dose protocol. The difference between two doses following chronic (1 mg kg-1 vs. 2.5 mg kg-1) and acute (6 vs. 15 mg kg-1) administration was 34.6 and 31.5%, respectively. Results of this investigation suggest that Doxo alone and in combination with Cipro from both the chronic and acute groups showed cardio-toxicity (release of cTnI). To our knowledge this is the first description towards Doxo-Cipro is induced cardiotoxicity and could be a bridge between preclinical and clinical practice for physicians in making an expert opinion dealing with above mentioned group.
PDF Fulltext XML References Citation

How to cite this article

Andleeb Shahzadi, Ikbal Sonmez, Oruc Allahverdiyev, Burak Onal, Cemre Kandaz, Sibel Ozmen Ozyazgan, Ahmet Gokhan Akkan and Zeliha Yazici, 2014. Cardiac Troponin-I (cTnI) a Biomarker of Cardiac Injuries Induced by Doxorubicin Alone and in Combination with Ciprofloxacin, Following Acute and Chronic Dose Protocol in Sprague Dawley Rats. International Journal of Pharmacology, 10: 258-266.

DOI: 10.3923/ijp.2014.258.266

URL: https://scialert.net/abstract/?doi=ijp.2014.258.266

Related Articles

Effect of Ciprofloxacin on the Plasma Concentration of Doxorubicin, Following Acute and Chronic Dose Protocol in Sprague Dawley Rats

Leave a Comment


Your email address will not be published. Required fields are marked *

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved